ArticleAnnals of medicine and surgery (2012)2025
Efficacy and safety of tafolecimab in Chinese patients with familial hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Familial hypercholesterolemia (FH) is a prevalent inherited disorder marked by elevated low-density lipoprotein cholesterol (LDL-C) levels, predisposing individuals to premature cardiovascular disease and related morbidities. Traditional treatments often fail to achieve target LDL-C levels in many patients, necessitating novel therapies. Tafolecimab, a monoclonal antibody targeting PCSK9, shows promise in managing HeFH by enhancing LDL receptor recycling and LDL-C clearance. Objective: To evaluate the efficacy and safety of tafolecimab in Chinese patients with FH through a systematic review and meta-analysis. Methods: This meta-analysis followed PRISMA guidelines and was registered in Prospective Register of Systematic Reviews. A comprehensive search was conducted across PubMed/MEDLINE, Web of Science, Scopus, and Embase databases. Inclusion criteria focused on randomized controlled trials (RCTs) involving patients aged 18-75 with hypercholesterolemia and high cardiovascular risk. Data extraction and quality assessment were performed independently by two reviewers. Statistical analyses were conducted using random-effects models. Results: Four RCTs involving 841 Chinese patients were included. Tafolecimab significantly reduced LDL-C (mean difference [MD]: -2.05; 95% CI: -2.19 to -1.90), apolipoprotein levels (MD: -0.53; 95% CI: -0.56 to -0.50), non-HDL-C (MD: -2.19; 95% CI: -2.32 to -2.06), and lipoprotein(a) levels (MD: -0.09; 95% CI: -0.11 to -0.07). The incidence of adverse events was higher in the tafolecimab group (risk ratio: 0.68; 95% CI: 0.61, 0.75), but no significant differences were found in serious adverse events, treatment discontinuation due to adverse events, deaths, hypersensitivity, muscle-related problems, upper respiratory issues, or liver damage compared to placebo. Conclusion: Tafolecimab effectively reduces various lipid parameters, suggesting its potential in managing hypercholesterolemia and reducing cardiovascular risk. Although adverse events were more frequent, their severity did not significantly differ from placebo. The generalizability of these findings is limited to Chinese populations, highlighting the need for further research in diverse cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.